Pharma Content Marketing
Scientific storytelling that passes
medical legal review
Life sciences content cannot afford factual ambiguity. We combine doctoral-level scientific writing with deep familiarity in Veeva Vault MLR workflows, producing disease state education, physician slide decks, and plain-language trial summaries that educate healthcare professionals while keeping regulatory affairs teams completely confident.
Request a pharma content reviewWhat does a pharma content marketing agency do?
A pharma content marketing agency produces scientific communications, medical writing, and regulatory-compliant digital content for pharmaceutical, biotechnology, and medical technology brands. The service spans unbranded disease state education, mechanism of action (MoA) visual narratives, physician-directed clinical whitepapers, and patient advocacy resources—all developed under formal Medical Legal Regulatory (MLR) oversight and referenced directly to peer-reviewed clinical studies.
Why typical agency content fails inside pharma
Generalist agencies waste months in review cycles because their writers do not understand regulatory substantiation.
Generalist Marketing Agency
Unreferenced Marketing Claims
- Writing unverified assertions that create severe regulatory red flags
- Zero reference annotations or line-by-line citation anchoring in source files
- Unfamiliarity with Veeva Vault, PromoMats, or formal MLR submission protocols
- Treating scientific mechanisms like consumer product benefits
- Endless revision rounds that delay product launch timelines by quarters
Oneskai Scientific Editorial
MedComms Rigor & MLR Velocity
- Doctoral and master’s-level medical writers (PharmD, PhD) with deep therapeutic literacy
- Full reference binder preparation with every claim anchored to primary literature
- Native workflow integration with Veeva Vault PromoMats and Aprimo systems
- Precise adherence to FDA Office of Prescription Drug Promotion (OPDP) guardrails
- Fast review cycles that accelerate time-to-market for critical clinical assets
Our editorial team operates with formal Medical Affairs and Commercial compliance discipline.
Four content formats that educate clinicians and patients
The scientific assets that drive meaningful therapeutic comprehension.
Unbranded disease state education hubs
Before introducing a novel mechanism, physicians and patients must understand underlying pathophysiology and diagnostic gaps. We build comprehensive, unbranded medical education portals that explain disease mechanisms, early detection criteria, and unmet clinical needs.
Pre-launch medical educationMechanism of Action (MoA) interactive narratives
Complex cellular biology and pharmacology require clear visual communication. We write and storyboard interactive, step-by-step MoA experiences that illustrate how your molecule engages its receptor and modulates disease pathways.
Visual pharmacology proofPlain Language Summaries of Publications (PLSPs)
Patients, caregivers, and patient advocacy organizations increasingly seek primary clinical trial data. We translate complex statistical trial results into accessible, peer-reviewed plain-language summaries that foster transparent patient empowerment.
Ethical patient advocacyMedical congress coverage & scientific symposium briefs
When new Phase III data drops at major congresses (ASCO, ESMO, AHA), timing is critical. We produce rapid, compliant executive summaries and scientific takeaways that synthesize key clinical presentations for broader medical community review.
Real-time scientific impact
Our MLR-aligned editorial workflow
Scientific literature review & claim substantiation
Our medical writers conduct primary literature searches and develop comprehensive reference binders linking every proposed statement to peer-reviewed data.
Veeva Vault reference anchoring & drafting
We draft content with direct reference callouts and prepare pre-annotated PDF packages formatted precisely for your internal Veeva PromoMats submission.
MLR committee collaboration & final sign-off
We participate in review discussions alongside your medical, legal, and regulatory reviewers, addressing comments rapidly to secure formal commercial approval.
We adhere strictly to evidence-based medical consensus. We will not draft claims that stretch beyond approved regulatory labels or distort primary clinical trial endpoints.
Questions
- What credentials do your pharmaceutical writers have?
- Our life sciences content team includes medical writers with advanced clinical degrees (PharmDs, PhDs, MDs) and specialized backgrounds in clinical research, medical journalism, and healthcare communications.
- How do you handle Veeva Vault PromoMats submissions?
- We prepare submission packages following strict industry standards: highlighted and annotated reference PDFs, clear claim-to-citation mappings, and structured asset metadata ready for immediate ingestion into Veeva Vault.
- What is the role of unbranded content in pharmaceutical marketing?
- Unbranded content focuses on disease awareness, epidemiology, and diagnostic challenges without mentioning specific therapies. It allows pharmaceutical companies to educate physicians and patients legally, even prior to formal drug approval.
- How do you ensure content complies with FDA Fair Balance rules?
- Whenever a drug name or indication is discussed in branded content, we ensure that Important Safety Information (ISI), contraindications, and boxed warnings are presented with equal prominence and formatting as required by FDA guidance.
- Can you produce content for medical affairs as well as commercial teams?
- Yes. We produce non-promotional, strictly educational scientific communications for Medical Affairs teams, as well as compliant promotional assets for Commercial and Brand teams.
Sources
- International Society for Medical Publication Professionals (ISMPP) Good Publication Practice (GPP).
- FDA Guidance for Industry: Presenting Risk Information in Prescription Drug and Medical Device Promotion.
- American Medical Writers Association (AMWA) Code of Ethics.
Related
Accelerate your scientific content approvals
Request a pharma content review. We will evaluate your current patient and HCP educational assets, reference workflows, and MLR turnaround velocity.
Confidential review under mutual NDA. Full regulatory assessment included.